Table 1.
Efficacy outcomes per central review at 42 months
| laBCC | mBCC | |||
|---|---|---|---|---|
| 200 mg (n = 66) | 800 mg (n = 128) | 200 mg (n = 13) | 800 mg (n = 23) | |
| ORR, % (95% CI) | 56 (43–68) | 46·1 (37·2–55·1) | 8 (0·2–36) | 17 (5–39) |
| CR, % (95%, CI) | 5 (0·9–13) | 1·6 (0·2–5·5) | 0 (0–25) | 0 (0–15) |
| DCR, % | 91 | 82·0 | 92 | 91 |
| DOR, median, months (95% CI) | 26·1 (NE) | 23·3 (12·2–29·6) | 24·0 (NE) | NE (NE) |
| PFS, median, months (95% CI) | 22·1 (NE) | 24·9 (19·2–33·4) | 13·1 (5·6–33·1) | 11·1 (7·3–16·6) |
| TTR, median, months (95% CI) | 4·0 (3·8–5·6) | 3·8 (3·7–5·5) | 9·2 (NE) | 1·0 (1·0–2·1) |
The results are for the intent‐to‐treat population. BCC, basal cell carcinoma; CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; laBCC, locally advanced BCC; mBCC, metastatic BCC; NE, not estimable; ORR, objective response rate; PFS, progression‐free survival; TTR, time to tumour response.